US-based medical technology firm Becton Dickinson (BD) has completed a $12.2bn acquisition of biomedical equipment maker CareFusion.
First announced in October 2014, the acquisition received approval from the European Commission under EU Merger Regulation.
As part of the transaction, BD paid $58 per share in cash and stock to shareholders of the US-based biomedical equipment maker.
Under the deal, CareFusion shareholders received $49 in cash and 0.0777 of a share of BD for each share of CareFusion, and the company is allowed to become a wholly-owned subsidiary of BD.
BD shareholders currently own 92% of the combined company and CareFusion shareholders will own the remaining 8%.
BD president Vincent Forlenza said: "We are very excited to announce the consummation of the CareFusion acquisition, as it represents a major milestone in BD’s 118-year history.
"We look forward to the future with confidence as we become one of the largest global leaders in medical technology, and are better positioned to partner with healthcare providers around the world to provide safer, more economical and improved care."
As a result of the acquisition, CareFusion is now a wholly-owned subsidiary of BD, while its shares stopped trading, and will be delisted from New York Stock Exchange (NYSE).
In the second half of fiscal year 2015, CareFusion will be included in a new BD Medical segment structure.
CareFusion develops Alaris infusion pumps and IV sets, MaxPlus and MaxZero IV connectors and sets, Pyxis automated dispensing and patient identification systems.
The company also produces AVEA, LTV series, AirLife ventilator and respiratory products, ChloraPrep products, MedMined services for data mining surveillance, V Mueller surgical instruments, as well as products that support interventional medicine.